11170376001
Roche
Anti-Bromodeoxyuridine
from mouse IgG1 (clone: BMC9318)
Synonyme(s) :
anti-BrdU, antibody
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Produits recommandés
Source biologique
mouse
Niveau de qualité
Conjugué
unconjugated
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
BMC9318, monoclonal
Pureté
90% (HPLC and SDS-PAGE)
Forme
solution
Conditionnement
pkg of 50 μg (500 μl)
Fabricant/nom de marque
Roche
Isotype
IgG1
Température de stockage
−20°C
Description générale
Anti-Bromodeoxyuridine is a monoclonal antibody to 5-bromo-2′-deoxyuridine-5′-monophosphate.
Spécificité
The antibody specifically binds to bromodeoxyuridine and crossreacts with iodouridine (10%). Anti-bromo-deoxyuridine does not crossreact with fluorodeoxy-uridine, nor with any endogenous cellular components such as thymidine or uridine.
Immunogène
The epitope is apparently inside the DNA helix. DNA has to be denatured to ssDNA before antibody efficiently binds to DNA-BrdU.
Application
Anti-bromodeoxyuridine (Anti-BrdU) antibody is suitable for monitoring proliferating cells in blood, tissues, and tumors, as well as for determining BrdU incorporation on a single-cell level using:
- Flow cytometry
- Immunohistocytochemistry
- Cryosections
- Paraffin sections
Qualité
The antibody is ≥90% pure as determined by SDS-PAGE with Coomassie-blue staining, and by HPLC.
Caractéristiques
Preparation: BALB/c mice were immunized with a bromodeoxyuridine-bovine serum albumin conjugate. Lymphocytes isolated from the spleen were fused with Ag8.653 myeloma cells to create the BMC 9318 clone. The antibody was produced in ascites in BALB/c mice and purified by ion-exchange chromatography.
No. of tests: 250 (Flow cytometry)
No. of tests: 250 (Flow cytometry)
Forme physique
Solution, stabilized with phosphate buffered saline, pH 7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) gelatin.
Notes préparatoires
Working concentration: Flow cytometry: 2 μg/ml (0.2 μg/100 μl/106 cells); Immunohistocytochemistry: 6 μg/ml
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Remarque sur l'analyse
Anti-Bromodeoxyuridine shows 10% cross reaction with iodo-deoxyuridine, but no cross reaction to fluoro-deoxyuridine.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
Autres remarques
For life science research only. Not for use in diagnostic procedures.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
nwg
Point d'éclair (°F)
No data available
Point d'éclair (°C)
No data available
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Derek C Adams et al.
American journal of physiology. Renal physiology, 297(3), F809-F815 (2009-06-19)
Long-term pulse chase experiments previously identified a sizable population of BrdU-retaining cells within the renal papilla. The origin of these cells has been unclear, and in this work we test the hypothesis that they become quiescent early during the course
Wouter Laurentius Smit et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(41), 25560-25570 (2020-09-30)
Deregulated global mRNA translation is an emerging feature of cancer cells. Oncogenic transformation in colorectal cancer (CRC) is driven by mutations in APC, KRAS, SMAD4, and TP53, known as the adenoma-carcinoma sequence (ACS). Here we introduce each of these driver
Erika A Correll et al.
IBRO neuroscience reports, 10, 31-41 (2021-04-17)
It has been demonstrated that adult born granule cells are generated after traumatic brain injury (TBI). There is evidence that these newly generated neurons are aberrant and are poised to contribute to poor cognitive function after TBI. Yet, there is
Xuexiao Li et al.
Cell death discovery, 8(1), 323-323 (2022-07-17)
Myelodysplastic syndromes (MDS) are characterized by daunting genetic heterogeneity and a high risk of leukemic transformation, which presents great challenges for clinical treatment. To identify new chemicals for MDS, we screened a panel of FDA-approved drugs and verified the neutrophil
Victoria Sofía Berenice Wies Mancini et al.
Glia, 67(2), 291-308 (2018-11-21)
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young people with very few therapeutic options available for its progressive forms. Its pathophysiology involves demyelination and neurodegeneration apparently driven by microglial activation, which is physiologically
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique